SCHEMBL24944444

SCHEMBL24944444

CNc1nc(Nc2ccc(CN3CCN(C)CC3)c(Cl)c2)c(C(N)=O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 4/20 0.37
▸ BCR P11274 2/20 0.37
▸ IKBKE Q14164 2/20 0.36
▸ TBK1 Q9UHD2 2/20 0.36
▸ EML4 Q9HC35 8/20 0.36
▸ ALK Q9UM73 8/20 0.36
▸ EGFR P00533 1/20 0.36
▸ AXL P30530 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ RET P07949 3/20 0.35
▸ ROS1 P08922 3/20 0.35
▸ FLT3 P36888 3/20 0.35
▸ KDR P35968 1/20 0.35
▸ BRD4 O60885 1/20 0.34
▸ TNIK Q9UKE5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL29173306 0.97 ABL1 (0.36) ABL1BCRIKBKETBK1EML4
Formic Acid SCHEMBL30205502 0.97 ABL1 (0.36) ABL1BCRIKBKETBK1EML4
SCHEMBL29173374 0.92 ABL1 (0.37) ABL1BCREGFRAXLKDM4E
SCHEMBL30206314 0.92 ABL1 (0.37) ABL1BCREGFRAXLKDM4E
SCHEMBL24943840 0.90 IKBKE (0.46) IKBKETBK1EML4ALKAXL
SCHEMBL30205589 0.90 IKBKE (0.46) IKBKETBK1EML4ALKAXL
Formic Acid SCHEMBL30206367 0.87 IKBKE (0.43) IKBKETBK1EML4ALKAXL
SCHEMBL24943812 0.84 IKBKE (0.38) IKBKETBK1EML4ALKRET
SCHEMBL30205471 0.84 IKBKE (0.38) IKBKETBK1EML4ALKRET
SCHEMBL24944172 0.84 TBK1 (0.39) IKBKETBK1EML4ALKAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback